Given that the identification of biomarkers can develop patient-specific treatments and improve the clinical outcome of glioma patients [6–8], more and more molecular markers (IDH1/2, MGMT, ATRX, etc) have been identified, many of which are used for diagnosis, classification, therapy response assessment, and prognosis evaluation [9–13]. The gene discussed is IDH1; the disease is central nervous system cancer.